Advice

Advice

NICE is unable to recommend panitumumab with 5 fluorouracil, folinic acid and irinotecan (FOLFIRI) for previously treated metastatic colorectal cancer in adults because no evidence submission was received from the manufacturer or sponsor of the technology.

Since the publication of TA240, the population covered by the marketing authorisation for panitumumab has changed from 'patients with wild-type KRAS metastatic colorectal cancer' to 'patients with wild-type RAS metastatic colorectal cancer'.

  • National Institute for Health and Care Excellence (NICE)